A multicentre randomised phase III trial comparing pembrolizumab versus standard chemotherapy for advanced pre-treated malignant pleural mesothelioma

PROMISE-meso: PembROlizuMab Immunotherapy versus Standard chemotherapy for advanced prE-treated malignant pleural mesothelioma

Systemic chemotherapy is currently the international standard care of treatment for patients with advanced pleural mesothelioma, where surgery is not possible. However, the median survival for these patients is only 9-12 month and there is unmet need for an effective therapy for patients with relapsed pleural mesothelioma.

Pembrolizumab is a potent and highly selective antibody, designed to directly block the interaction between PD-1 and its ligands.

The aim of the PROMISE-meso trial is to investigate whether treatment with pembrolizumab improves progression-free survival (PFS) compared to standard chemotherapy (gemcitabine or vinorelbine).

Trial Scheme



Primary Endpoint: Progression-free survival based on independent review
Secondary Endpoints:

Objective response

Overall survival

Time to treatment failure

Investigator assessed progression-free survival

Tolerability of treatment

Target Sample Size: 142 Patients 
Final Accrual: 144 Patients
Protocol Release Date: 15 November 2016
Trial Activation Date: 02 May 2017
First Patient In: 12 September 2017
Accrual Closure Date: 14 August 2018
Global Trial Completion Date: 29 November 2021

Trial Organisation

Trial Chairs: Sanjay Popat and Alessandra Curioni-Fontecedro
Sponsor: ETOP IBCSG Partners
Coordinating Group: ETOP IBCSG Partners
Participating Groups: SAKK and SLCG
Participating Countries:
Spain, Switzerland, and United Kingdom

EudraCT number: 2016-002062-31

ClinicalTrials.gov: NCT02991482



Uli Kodjadjiku (Clinical Trial Manager)

This email address is being protected from spambots. You need JavaScript enabled to view it.


ETOP IBCSG Partners Foundation
Effingerstrasse 33
3008 Bern, Switzerland